- Home
- CPIX
as 09-17-2025 4:00pm EST
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NASHVILLE, |
| Market Cap: | 48.5M | IPO Year: | 2009 |
| Target Price: | N/A | AVG Volume (30 days): | 32.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $7.25 | Next Earning Date: | 11-06-2025 |
| Revenue: | $42,071,813 | Revenue Growth: | 11.34% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cumberland Pharmaceuticals Inc. (CPIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Caroline | CPIX | Director | Aug 29 '25 | Buy | $3.45 | 6 | $20.70 | 32,942 | |
| Krogulski Kenneth | CPIX | Director | Aug 29 '25 | Buy | $3.45 | 68 | $234.60 | 289,717 | |
| Jones James | CPIX | Director | Aug 29 '25 | Buy | $3.45 | 13 | $44.85 | 43,938 | |
| KAZIMI A J | CPIX | Chairman and CEO | Aug 29 '25 | Buy | $3.45 | 13 | $44.85 | 5,700,030 | |
| Young Caroline | CPIX | Director | Aug 28 '25 | Buy | $3.47 | 6 | $20.82 | 32,942 | |
| Krogulski Kenneth | CPIX | Director | Aug 28 '25 | Buy | $3.47 | 68 | $235.96 | 289,717 | |
| Jones James | CPIX | Director | Aug 28 '25 | Buy | $3.47 | 13 | $45.11 | 43,938 | |
| KAZIMI A J | CPIX | Chairman and CEO | Aug 28 '25 | Buy | $3.47 | 13 | $45.11 | 5,700,030 | |
| Young Caroline | CPIX | Director | Aug 27 '25 | Buy | $3.44 | 6 | $20.64 | 32,942 | |
| Krogulski Kenneth | CPIX | Director | Aug 27 '25 | Buy | $3.44 | 68 | $233.92 | 289,717 |
Latest Cumberland Pharmaceuticals Inc. News
CPIX Breaking Stock News: Dive into CPIX Ticker-Specific Updates for Smart Investing
PR Newswire
3 months ago
Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Simply Wall St.
4 months ago
Investors in Cumberland Pharmaceuticals (NASDAQ:CPIX) have seen splendid returns of 235% over the past year
PR Newswire
4 months ago
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
MT Newswires
4 months ago
Cumberland, Qureight Collaborate on Lung Disease Treatment Trial
PR Newswire
4 months ago
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
GuruFocus.com
4 months ago
Cumberland Pharmaceuticals Inc (CPIX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...
PR Newswire
4 months ago
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
PR Newswire
5 months ago
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
Compare CPIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CPIX Cumberland Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.